Emerging Trends In Immunotherapy Management For Pancreatic Cancer: A Literature Review

Abstract

The prognosis for pancreatic cancer (PC) is poor making it a substantial treatment challenge. A potentially effective treatment option is immunotherapy. To better understand the changing field of immunotherapy in PC management, this analysis will focus on important tactics and their consequences. To find relevant research published between 2019 and 2024, a thorough literature search was carried out using Scopus, Google Scholar, and PubMed. Tumor cells may be targeted and immune responses can be modulated using passive immunotherapeutic techniques such as CAR T-cell therapy and programmed death checkpoint inhibitors. Preclinical and clinical studies show enhanced effectiveness of combination therapy, such as anti-PD-1/anti-PD-L1 plus CTLA-4 inhibitors. Although their efficacy varies, active immunotherapeutic strategies, in particular cancer vaccines, seek to promote immune recognition of tumor antigens. Subpar response rates and treatment-related toxicity are obstacles. Checkpoint inhibitors, CAR T-cell therapy, and cancer vaccines are a few possible therapeutic options in the exciting field of immunotherapy for PC treatment. Nevertheless, further study is required to enhance these strategies and enhance patient.